Page 784 - Basic _ Clinical Pharmacology ( PDFDrive )

770 SECTION VII Endocrine Drugs

PREP AR A TIONS A V AIL ABLE *

GENERIC NAME AVAILABLE AS GENERIC NAME AVAILABLE AS
SULFONYLUREAS THIAZOLIDINEDIONE COMBINATION
Acetohexamide ‡ Generic, Dymelor Pioglitazone plus glimepiride Duetact
Chlorpropamide Generic, Diabinese Alogliptin plus pioglitazone Oseni
Gliclazide ‡ Generic, Diamicron Rosiglitazone plus glimepiride Avandaryl
Glimepiride Generic, Amaryl ALPHA-GLUCOSIDASE INHIBITORS
Glipizide Generic, Glucotrol, Glucotrol XL Acarbose Generic, Precose
Glyburide Generic, Diaβeta, Micronase, Miglitol Glyset
Glynase PresTab Voglibose ‡
Tolazamide Generic, Tolinase GLUCAGON-LIKE POLYPEPTIDE-1 RECEPTOR AGONISTS
Tolbutamide Generic, Orinase Exenatide Byetta
MEGLITINIDES Liraglutide Victoza
Repaglinide Generic, Prandin Albiglutide Tanzeum, Eperzan
Mitiglinide ‡ Dulaglutide Trulicity
d-PHENYLALANINE DERIVATIVE DIPEPTIDYL PEPTIDASE-4 INHIBITORS
Nateglinide Generic, Starlix Linagliptin Tradjenta
BIGUANIDE Saxagliptin Onglyza
Metformin Generic, Glucophage, Sitagliptin Januvia
Glucophage XR Alogliptin Nesina
METFORMIN COMBINATIONS † Vildagliptin ‡
Glipizide plus metformin Generic, Metaglip SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS
Glyburide plus metformin Generic, Glucovance Canagliflozin Invokana
Pioglitazone plus metformin ACTOplus Met Dapagliflozin Farxiga
Repaglinide plus metformin Prandi-Met Empagliflozin Jardiance
Rosiglitazone plus metformin Avandamet SODIUM GLUCOSE CO-TRANSPORTER
Saxagliptin plus metformin Kombiglyze INHIBITORS COMBINATION
Sitagliptin plus metformin Janumet Empagliflozin plus linagliptin Glyxambi
Linagliptin plus metformin Jentadueto ISMISCELLANEOUS DRUGSLET AMYLOID POLYPEPTIDE ANALOG
Alogliptin plus metformin Kazano Pramlintide Symlin
Dapagliflozin plus metformin Xigduo BILE ACID SEQUESTRANT
Canagliflozin plus metformin Invokamet Colesevelam hydrochloride Welchol
Empagliflozin plus metformin Synjardy DOPAMINE RECEPTOR AGONIST
THIAZOLIDINEDIONE DERIVATIVES Bromocriptine Generic, Parlodel, Cycloset
Pioglitazone Generic, Actos GLUCAGON
Rosiglitazone Avandia Glucagon Generic
*
See Table 41–5 for insulin preparations.
† Other combinations are available.
‡
Not available in the United States.

REFERENCES Andrianesis V, Doupis J: The role of kidney in glucose homeostasis—SGLT2
inhibitors, a new approach in diabetes treatment. Expert Rev Clin Pharma-
col 2013;6:519.
Action to Control Cardiovascular Risks in Diabetes Study Group: Effects of
intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545. Bennett WL et al: Comparative effectiveness and safety of medications for type
2 diabetes: An update including new drugs and 2-drug combinations. Ann
Adler AI et al: Association of systolic blood pressure with macrovascular and Intern Med 2011;154:602. Erratum in: Ann Intern Med 2011;155:67.
microvascular complications of type 2 diabetes (UKPDS 36): Prospective
observational study. Br Med J 2000;321:412. Butler PC et al: A critical analysis of the clinical use of incretin-based therapies: Are
the GLP-1 therapies safe? Diabetes Care 2013;36:2118.
ADVANCE Collaborative Group: Intensive blood glucose control and vascular
outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560. Diabetes Prevention Program Research Group: Reduction in the incidence of
type 2 diabetes with lifestyle intervention or metformin. N Engl J Med
Ahmadian M et al: PPARγ signaling and metabolism: The good, the bad and the 2002;346:393.
future. Nat Med 2013;19:557. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Report of the Expert Committee on the Diagnosis and Classification of
Diabetes Care 2013;36(Suppl 1):S67. Diabetes Mellitus. Diabetes Care 2003;26(Suppl 1):S5.